We describe the novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium (M. genitalium) infection in a 20-year-old heterosexual cisgender male presenting with recurrent symptomatic non-gonococcal urethritis. M. genitalium urethritis is an increasingly common clinical conundrum in sexual health clinics and in cases of second-line treatment failure (such as moxifloxacin), UK and international guidelines struggle to make recommendations for third-line treatments. As shown in our case, the evidence base for third-line treatments is lacking, with poor success rates, and may be poorly tolerated. Here we demonstrate the novel use of a well-tolerated oral antimicrobial, chloramphenicol, resulting in rapid microbiological and clinical cure in treatment-resistant M. genitalium urethritis.
CITATION STYLE
Goodfellow, J. J., Hughes, S., Smith, J., Jones, R., Moore, L. S. P., & Rayment, M. (2023). Novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium. Sexually Transmitted Infections, 99(3), 208–210. https://doi.org/10.1136/sextrans-2022-055621
Mendeley helps you to discover research relevant for your work.